Loading…
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-64M | $-57M | $-56M | -29.2% | - | - |
| 2024 | $0M | $-49M | $-45M | $-36M | -26.7% | - | - |
| 2023 | $0M | $-43M | $-40M | $-38M | -59.2% | - | - |
| 2022 | $0M | $-65M | $-66M | $-27M | -64.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 37.55 | 43.61 | 49.15 | 64.55 |
| Operating Income | -37.55 | -43.61 | -49.15 | -64.55 |
| EBITDA | -64.57 | -43.27 | -48.82 | -64.19 |
| EBIT | -64.81 | -43.61 | -49.15 | -64.55 |
| Pretax Income | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income Common Stockholders | -65.95 | -40.42 | -44.60 | -57.44 |
| Total Expenses | 37.55 | 43.61 | 49.15 | 64.55 |
| Interest Expense | 1.14 | 0 | 0 | 0 |
| Interest Income | 2.23 | 3.18 | 4.13 | 6.33 |
| Research And Development | 16.81 | 24.99 | 31.70 | 42.63 |
| Selling General And Administration | 20.74 | 18.62 | 17.45 | 21.92 |
| Normalized EBITDA | -35.07 | -43.28 | -48.86 | -64.24 |
| Normalized Income | -36.45 | -40.43 | -44.63 | -57.49 |
| Basic EPS | -5.86 | -3.57 | -2.17 | 0 |
| Diluted EPS | -5.86 | -3.57 | -2.17 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -29.50 | 0.01 | 0.04 | 0.05 |
| Total Unusual Items Excluding Goodwill | -29.50 | 0.01 | 0.04 | 0.05 |
| Net Income From Continuing Operation Net Minority Interest | -65.95 | -40.42 | -44.60 | -57.44 |
| Reconciled Depreciation | 0.25 | 0.34 | 0.33 | 0.36 |
| Net Interest Income | 1.09 | 3.18 | 4.13 | 6.33 |
| Net Income From Continuing And Discontinued Operation | -65.95 | -40.42 | -44.60 | -57.44 |
| Total Operating Income As Reported | -67.06 | -43.61 | -49.15 | -64.55 |
| Diluted Average Shares | 11.26 | 11.33 | 20.59 | 0 |
| Basic Average Shares | 11.26 | 11.33 | 20.59 | 0 |
| Diluted NI Availto Com Stockholders | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income Including Noncontrolling Interests | -65.95 | -40.42 | -44.60 | -57.44 |
| Net Income Continuous Operations | -65.95 | -40.42 | -44.60 | -57.44 |
| Other Income Expense | -29.50 | 0.01 | 0.42 | 0.78 |
| Other Non Operating Income Expenses | 0 | 0 | 0.39 | 0.73 |
| Special Income Charges | -29.52 | 0 | 0 | 0 |
| Impairment Of Capital Assets | 29.52 | 0 | 0 | 0 |
| Gain On Sale Of Security | 0.02 | 0.01 | 0.04 | 0.05 |
| Net Non Operating Interest Income Expense | 1.09 | 3.18 | 4.13 | 6.33 |
| Interest Expense Non Operating | 1.14 | 0 | 0 | 0 |
| Interest Income Non Operating | 2.23 | 3.18 | 4.13 | 6.33 |
| General And Administrative Expense | 20.74 | 18.62 | 17.45 | 21.92 |
| Other Gand A | 20.74 | 18.62 | 17.45 | 21.92 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Protara Therapeutics, Inc.this co. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| Greenwich LifeSciences, Inc. | GLSI | $299M | - | 136.71 | -623.1% | -15.09 |
| Rezolute, Inc. | RZLT | $299M | - | 2.53 | -45.9% | -1.89 |
| Organogenesis Holdings Inc. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| LENZ Therapeutics, Inc. | LENZ | $284M |
| - |
| 1.00 |
| -28.9% |
| 0.09 |
| Simulations Plus, Inc. | SLP | $283M | - | 2.11 | -51.9% | 17.29 |
| RxSight, Inc. | RXST | $282M | - | 1.02 | -14.1% | -1.42 |
| Foghorn Therapeutics Inc. | FHTX | $279M | - | -2.49 | 68.5% | -2.05 |
| Editas Medicine, Inc. | EDIT | $276M | - | 10.11 | -586.6% | -1.57 |
| Peer Median | - | 15.33 | 1.57 | -37.4% | -1.50 | |